The use of the immunizer had been paused in the country on April 13 after registering a series of cases of cerebral thrombosis in vaccinated women. The measure had been suggested hours earlier by an independent panel of experts.
The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) Authorized this Friday to resume the administration of the vaccine against covid-19 of Janssen, a subsidiary of Johnson & Johnson, after a pause for the detection of several cases of thrombosis.
The move came just hours after an advisory committee of experts from the CDC - which has also evaluated the safety of vaccines before their initial authorization - recommended it.
Johnson's Covid-19 vaccine is approved for people 18 years of age and older in the U.S. population under the FDA's Emergency Use Permit, the group formed by the CDC said.
The 15 experts of the Advisory Committee on Immunization Practices (ACIP) of the CDC spoke out overwhelmingly in favor of this recommendation in a vote, in which ten supported resuming vaccination with this serum, compared to 4 who opposed and one abstention.
Of the 3.9 million women who received the Johnson & Johnson vaccine, 15 developed blood clots, and three died, according to data released Friday.
Most of these women, 13 out of 15, were under the age of 50. During the meeting, one specialist mentioned that there could be potential cases in infected vaccinated men. However, they have not yet been confirmed and are being studied.
Despite giving the green light, they pointed out that a warning about possible health risks should accompany the vaccine.
CDC Director Rochelle Walensky must now sign the ACIP recommendation before the Food and Drug Administration (FDA) undertakes any changes to the J&J vaccine labeling.
The committee meeting was attended by representatives of J&J, who stated before the vote that they had agreed with the FDA to include in the labeling the notice that there could be a risk of blood clots.
On Tuesday, the European Medicines Agency (EMA) said it had found a possible link between vaccines and unhealthy blood clotting problems in adults taking food in the United States but added that the benefits of injections outweighed the risks.
The new cases of Oregon and Texas that were known in the press
One of them is an Oregon woman, in her 50s, who received the vaccine before the order to pause the inoculant was issued, state health authorities said in a statement.
The Oregon Health Authority added that within two weeks of receiving the vaccine, it had developed a rare but serious blood clot that had been mixed with very few platelets.
A spokesman for the Texas health agency said; meanwhile, a Texas woman who received the Johnson & Johnson vaccine has been hospitalized for symptoms similar to those of six people who recently suffered blood clots after receiving the injection in the United States.
Both states confirmed that the new cases were independent of the six previous incidents.